Buprenorphine is used for opioid dependence substitution therapy. Its pharmacological advantage over methadone in preventing overdose is based on:

• A Buprenorphine is a full agonist at μ-opioid receptors with a ceiling effect due to high first-pass metabolism
• B Buprenorphine's partial agonism at μ-opioid receptors produces a ceiling effect on respiratory depression but not on analgesic/euphoric effects, providing a safety margin ✓
• C Buprenorphine is a κ-opioid receptor antagonist only, lacking μ-receptor activity and thus preventing respiratory depression
• D Buprenorphine's high protein binding prevents CNS penetration at high doses, creating an auto-limiting ceiling effect

Explanation

Buprenorphine is a partial agonist at μ-opioid receptors and an antagonist at κ-opioid receptors. Its partial agonism means intrinsic efficacy at μ receptors is submaximal; even at very high doses, maximal μ-receptor activation is not achieved, producing a ceiling on respiratory depression. This is the pharmacodynamic basis of its safety in overdose. However, buprenorphine also has a ceiling on analgesia (limiting its use in severe pain). Its very high receptor affinity (Kd ~1 nM) and slow dissociation from μ receptors (half-life at receptor ~166 min) makes it resistant to naloxone reversal; high doses of naloxone or infusion may be needed. Naloxone is included in Suboxone to deter intravenous misuse.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.